{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:44:48Z","timestamp":1773434688129,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ahj.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T03:51:14Z","timestamp":1673581874000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor"],"prefix":"10.1016","volume":"258","author":[{"given":"Matthew","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritha J.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gearoid","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-564X","authenticated-orcid":false,"given":"Alexander","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2023.01.002_bib0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2023.01.002_bib0002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0003","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.01.002_bib0004","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0006","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin\u2013angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0008","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1053\/j.ajkd.2005.08.034","article-title":"Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies","volume":"46","author":"Aranda","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2023.01.002_bib0009","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0011","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Investigators","year":"2000","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0012","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.jacc.2004.01.041","article-title":"Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge","volume":"43","author":"Butler","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0013","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cardfail.2017.09.014","article-title":"Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry","volume":"23","author":"Zhang","year":"2017","journal-title":"J Cardiac Fail"},{"key":"10.1016\/j.ahj.2023.01.002_bib0014","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.106.657601","article-title":"Regional differences in process of care and outcomes for older acute myocardial infarction patients in the United States and Ontario, Canada","volume":"115","author":"Ko","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2023.01.002_bib0015","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.ajkd.2005.08.018","article-title":"Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes","volume":"46","author":"Winkelmayer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2023.01.002_bib0016","doi-asserted-by":"crossref","first-page":"649","DOI":"10.18553\/jmcp.2006.12.8.649","article-title":"Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization","volume":"12","author":"Cooke","year":"2006","journal-title":"J Managed Care Pharm"},{"key":"10.1016\/j.ahj.2023.01.002_bib0017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1161\/HYPERTENSIONAHA.120.16281","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use among hypertensive US adults with albuminuria","volume":"77","author":"Chu","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.01.002_bib0018","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2023.01.002_bib0019","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2023.01.002_bib0020","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehi499","article-title":"Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure","volume":"26","author":"Lenzen","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.002_bib0021","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2165\/00003495-200161140-00002","article-title":"Underutilisation of ACE inhibitors in patients with congestive heart failure","volume":"61","author":"Bungard","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2023.01.002_bib0022","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0023","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","article-title":"Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study","volume":"16","author":"Schmieder","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0024","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2023.01.002_bib0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40620-015-0256-3","article-title":"How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT\u2014a prospective cohort study","volume":"30","author":"Cianfrone","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0026","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0027","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0028","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.01.002_bib0029","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2215\/CJN.12990820","article-title":"Ambulatory treatments for RAAS inhibitor-related hyperkalemia and the 1-year risk of recurrence","volume":"16","author":"Hundemer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2023.01.002_bib0031","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2023.01.002_bib0032","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ahj.2023.01.002_bib0033","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12882-019-1250-0","article-title":"Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England","volume":"20","author":"Horne","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0034","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/0886022X.2016.1216714","article-title":"Community-acquired hyperkalemia in elderly patients: risk factors and clinical outcomes","volume":"38","author":"Turgutalp","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.ahj.2023.01.002_bib0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/j.ajkd.2021.07.008","article-title":"Population epidemiology of hyperkalemia: cardiac and kidney long-term health outcomes","volume":"79","author":"Mclean","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2023.01.002_bib0036","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0037","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ackd.2017.06.004","article-title":"Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes","volume":"24","author":"Gilligan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ahj.2023.01.002_bib0038","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5114\/aoms.2014.42577","article-title":"Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes","volume":"10","author":"Khanagavi","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.ahj.2023.01.002_bib0039","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How dangerous is hyperkalemia?","volume":"28","author":"Montford","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0040","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1093\/ckj\/sfab029","article-title":"Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD)","volume":"14","author":"Humphrey","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ahj.2023.01.002_bib0041","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/ndt\/gfaa300","article-title":"Renin\u2013angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease","volume":"36","author":"Walther","year":"2021","journal-title":"Nephrology Dial Transplant"},{"key":"10.1016\/j.ahj.2023.01.002_bib0042","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ahj.2021.09.014","article-title":"Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes","volume":"243","author":"Xu","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2023.01.002_bib0043","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.01.002_bib0044","unstructured":"Beusekamp JC. Hyperkalemia is independently associated with unsuccessful ACE-I\/ARBs uptitration in heart failure patients with reduced ejection fraction; 2016. More information is available at https:\/\/umcg.studenttheses.ub.rug.nl\/775\/"},{"key":"10.1016\/j.ahj.2023.01.002_bib0045","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000013599","article-title":"Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors","volume":"20","author":"Ahuja","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0046","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2023.01.002_bib0047","doi-asserted-by":"crossref","first-page":"F593","DOI":"10.1152\/ajprenal.00454.2003","article-title":"Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule","volume":"287","author":"Meneton","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0048","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1046\/j.1523-1755.2003.00124.x","article-title":"A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease","volume":"64","author":"Vasavada","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2023.01.002_bib0049","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2023.01.002_bib0050","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.002_bib0051","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40620-018-0502-6","article-title":"Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice","volume":"31","author":"De Nicola","year":"2018","journal-title":"J Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0052","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2023.01.002_bib0053","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2023.01.002_bib0054","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2023.01.002_bib0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870323000133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870323000133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:09:51Z","timestamp":1757570991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870323000133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":55,"alternative-id":["S0002870323000133"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2023.01.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}